Cancer therapy developer Oric, whose backers include Memorial Sloan, Taiho and Hartford HealthCare, floated at the top of its range in an expanded IPO.
Oric Pharmaceuticals, a US-based cancer therapy developer backed by corporate investors Taiho, Hartford HealthCare and Memorial Sloan Kettering Cancer Center, went public on Friday in a $120m initial public offering.
The IPO consisted of 7.5 million shares priced at the top of its $14 to $16 range. Oric had initially sought to issue 5 million shares in the offering and had increased the number to 6.3 million last week.
The company’s shares opened at $26.00 each on the Nasdaq…
